DocGo Inc. DCGO NASDAQ · Healthcare · United States
$0.18 -3.53% -$0.01
Summary
40 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It bought back its own shares for $10.8M in the last fiscal year, 60% of its market value.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 9.9% a year over the last 3 years.
- It missed profit estimates 7 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 28% a year over 5 years. Over the last 3 years it fell by 9.9% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $181.3M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $5.84 is 3,088% above today's price. 88% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Transportation Services Segment 62%
- Mobile Health Services Segment 38%
By region
- UNITED STATES 83%
- UNITED KINGDOM 17%
Transportation Services Segment brings in 62% of revenue.
Segments in detail